Food Oral Immunotherapy, Candidacy & Management

Candidate selection and management of food oral immunotherapy (OIT), regular ingestion of increasing allergen doses to raise the reaction threshold (desensitization). Covers who is a candidate, the build-up vs maintenance phases, adverse-event handling (dosing reactions, OIT-induced EoE, cofactor effects), and the key counseling point that protection requires ongoing daily dosing and OIT increases treatment-phase reactions versus avoidance.

Evidence tier: Guideline-derived.

Decision points

  • Is the patient a candidate for OIT?
  • Tolerating updosing, or recurrent/systemic reactions?

Do-not-miss pitfalls

  • OIT is desensitization, not a cure, protection depends on CONTINUED daily dosing. Counsel that stopping or interrupting dosing (e.g., during illness or travel) can cause the threshold to fall and reactions to recur.
  • OIT increases reactions during the treatment phase compared with avoidance, including systemic reactions and epinephrine use. The trade-off (higher threshold vs more treatment-phase reactions and daily burden) must be an explicit shared decision.
  • Uncontrolled or severe asthma is a major risk factor for severe OIT reactions, optimize asthma before and throughout OIT, and reconsider OIT if asthma is not controllable.
  • Cofactors lower the reaction threshold during OIT, exercise, fever/illness, menses, NSAIDs, and empty-stomach dosing. Rest after dosing, avoid exercise around dosing, and hold/reduce the dose during intercurrent illness.
  • OIT can induce eosinophilic esophagitis, new dysphagia, food impaction, or recurrent vomiting/abdominal pain warrants endoscopic evaluation; OIT-induced EoE usually resolves after stopping OIT.
  • Sustained unresponsiveness (tolerance persisting off-therapy) is achieved by only a minority, most patients remain desensitized only while dosing. Do not promise a durable cure.
  • AR101 (Palforzia) is approved for peanut ages 1-17, and the manufacturer has announced discontinuation effective 31 July 2026; other-food and adult OIT are less standardized, match the protocol to the evidence and set expectations accordingly.
  • Omalizumab is now FDA-approved for IgE-mediated food allergy, it is an alternative for non-candidates and an adjunct that can improve OIT tolerability and thresholds.

Evidence & citations

  1. Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73(4):799-815. PMID 29205393
  2. PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991-2001. PMID 30449234
  3. Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468-475. PMID 24361082
  4. Riggioni C, Riggioni C, Comberiati P, et al. Immunotherapy and biologics in the management of IgE-mediated food allergy: systematic review and meta-analyses of efficacy and safety. Allergy. 2024;79(8):2097-2127. PMID 38747333

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.